Stock Events

Stock Events

Pharmaust 

A$0.23
6
-A$0-0% Monday 05:10

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29JulExpected
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Q2 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-18,020.48%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
83,000Revenue
-14.96MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PAA.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.57B
Zai Lab Limited operates in the biopharmaceutical sector focusing on developing and commercializing therapies that address significant unmet medical needs, similar to Pharmaust's focus on innovative cancer treatments.
Macrogenics
MGNX
Mkt Cap193.86M
MacroGenics, Inc. develops monoclonal antibody-based therapeutics for the treatment of cancer, aligning closely with Pharmaust's work in cancer therapeutics.
Karyopharm Therapeutics
KPTI
Mkt Cap195.23M
Karyopharm Therapeutics Inc. is involved in the discovery and development of drugs for the treatment of cancer, competing in the same therapeutic area as Pharmaust.
TG Therapeutics
TGTX
Mkt Cap5.85B
TG Therapeutics, Inc. focuses on B-cell malignancies and autoimmune diseases, competing with Pharmaust in the broader oncology and therapeutic market.
Array Technologies
ARRY
Mkt Cap1.24B
Array BioPharma Inc. specializes in the development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, similar to Pharmaust's strategic focus.

About

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.
Show more...
CEO
Dr. Michael Thurn Ph.D.
Country
Australia
ISIN
AU000000PAA1

Listings

OTC Link
US
NUZTF
STU
DE
ECQ0.STU
F
DE
ECQ0.F
AU
AU
NUZ.AU

0 Comments

Share your thoughts

FAQ

What is Pharmaust stock price today?▼
The current price of PAA.AU is A$0.23 AUD — it has decreased by -0% in the past 24 hours. Watch Pharmaust stock price performance more closely on the chart.
What is Pharmaust stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharmaust stocks are traded under the ticker PAA.AU.
What is Pharmaust revenue for the last year?▼
Pharmaust revenue for the last year amounts to 83,000 AUD.
What is Pharmaust net income for the last year?▼
PAA.AU net income for the last year is -14.96M AUD.
In which sector is Pharmaust located?▼
Pharmaust operates in the Health & Wellness sector.
When did Pharmaust complete a stock split?▼
The last stock split for Pharmaust was on October 30, 2015 with a ratio of 1:20.
Where is Pharmaust headquartered?▼
Pharmaust is headquartered in Melbourne, Australia.